Fiche centre
The Second Affiliated Hospital of Air Force Medical University
Xi'an — China
Essais liés2clinical trials
VilleXi'anlocalisation
PaysChinalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06958939
Essais cliniques associés
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Dose level 1 group | Myasthénie | Phase 1 | NCT06958939 | The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| RC18 160mg | Myasthénie | Phase 2 | NCT04302103 | A Study of TACI（Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor）-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis | COMPLETED |